Comparing Oncolytics Biotech (ONCY) & Its Competitors

Oncolytics Biotech (NASDAQ: ONCY) is one of 524 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Oncolytics Biotech to similar companies based on the strength of its risk, valuation, earnings, profitability, dividends, institutional ownership and analyst recommendations.

Volatility & Risk

Oncolytics Biotech has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Oncolytics Biotech’s rivals have a beta of 0.93, suggesting that their average share price is 7% less volatile than the S&P 500.


This table compares Oncolytics Biotech and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncolytics Biotech N/A -185.35% -98.72%
Oncolytics Biotech Competitors -2,656.08% -68.56% -24.44%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Oncolytics Biotech and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncolytics Biotech 0 0 1 0 3.00
Oncolytics Biotech Competitors 3679 10783 24600 804 2.57

As a group, “Pharmaceutical preparations” companies have a potential upside of 64.93%. Given Oncolytics Biotech’s rivals higher probable upside, analysts clearly believe Oncolytics Biotech has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Oncolytics Biotech and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oncolytics Biotech N/A -$12.04 million -3.46
Oncolytics Biotech Competitors $1.96 billion $127.69 million -8.05

Oncolytics Biotech’s rivals have higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

3.4% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 46.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 15.1% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


Oncolytics Biotech rivals beat Oncolytics Biotech on 8 of the 13 factors compared.

About Oncolytics Biotech

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with's FREE daily email newsletter.

Leave a Reply